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Lessons from cardiac transplantation in
infancy
Cardiac transplantation in the newborn and
in young infants corrects the devastating patho-
physiology of congenital heart disease and
cardiomyopathy, averting the morbidity and
mortality they might cause. While transplanta-
tion in the young ‘‘cures’’ cardiac disease, it might
also provide insights not otherwise available into
the structure and operation of the immune
system. The infant undergoing cardiac transplan-
tation is probably naı̈ve immunologically and
the response ensuing or lack thereof is unalloyed
by the function of memory lymphocytes that
accumulate with age. The procedure of cardiac
transplantation is often accompanied by removal
of the thymus, by depletion of mature T cells and
followed by life-long immunosuppression. These
manipulations in concert should deprive the
recipient of some measure of immunological
competence.
We have undertaken a collaboration to inves-
tigate the structure and function of the immune
system in those who undergo cardiac transplan-
tation in infancy. Here, we communicate the
current understanding of immune physiology
that sparked our interest in this subject and the
lessons, some quite surprising, which emerged.
The immune response to allotransplantation
in the young
Considering the very limited genetic diversity
among members of a species and the likelihood
that the immune system evolved to protect
against microbial organisms, one would predict
that immune responses to transplants would be
idiosyncratic and weak in comparison to immune
responses to microorganisms. But, such a pre-
diction would prove wrong. The immune system
responds more reliably, faster and more power-
fully to allotransplantation than it does to
infection. Whether this difference reflects funda-
mental differences in immune recognition
and effector functions or whether it might be
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Abstract: Besides correcting devastating pathophysiology, cardiac
transplantation in infancy offers an incomparable model for exploring
the structure and function of the immune system. Infants and young
children have relatively few memory B cells and T cells. Hence, the
response of the young to allotransplantation better represents a primary
immune response and may be better suited to testing spontaneous
tolerance. Those who undergo cardiac transplantation in infancy are
also unique because they are often subjected to thymectomy and
depletion of mature T cells. These subjects can have a dramatic
contraction of T cell diversity, allowing the testing of how diversity
contributes to function.
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explained by conventional immune physiology is
uncertain. As we shall explain, pediatric trans-
plantation and particularly cardiac transplanta-
tion in infancy might offer key insights on this
subject.
We describe the immune reaction to allotrans-
plantation in mature individuals as universal (it
occurs in every un-manipulated recipient), rapid
(it occurs in days) and quite severely destructive
(it completely destroys the target) (1). The
reaction is dominated by responses to allogeneic
antigens encoded in the MHC. In contrast,
immune responses to bacteria, viruses, fungi,
vaccines and other antigens, including minor
histocompatibility antigens occur sporadically
(e.g., the rate of response to BCG is 50% at
best), over periods of weeks or even months and
do not generally destroy the targeted cells, at
least not quickly. The difference between the
immune response to allografts and to all other
antigenic challenges could reflect the peculiar
way in which major histocompatibility antigens
are presented or it could reflect unanticipated
immunological memory, memory responses like
allogeneic responses being universal or nearly so,
rapid and highly effective (2, 3).
The mechanism by which T cells recognize
allogeneic cells might explain the universal, rapid
and highly destructive allogeneic response. T cells
can recognize allogeneic cells ‘‘directly’’; that
is, T cells recognize intact allogeneic MHC
expressed on allogeneic antigen-presenting cells.
By direct recognition a T cell can potentially
engage a large fraction of a given MHC on
antigen-presenting cells (because peptide plays a
nominal role) (4) or because the receptor can
recognize many peptides (5). Hence, direct rec-
ognition activates up to 30% of T cells (4, 6) and
responses occur always or nearly always so that
the responses can be used to test for MHC class
II and to map MHC (7). In contrast, T cells
recognize other antigens, such as toxins, bacterial
and viral proteins, as degraded foreign peptides
associated with MHC on autologous antigen-
presenting cells. When T cells recognize antigen
on autologous antigen-presenting cells, ‘‘indi-
rectly’’ as such, only a small fraction of MHC
complexes on the autologous cells contain a
given peptide. Hence, indirect recognition acti-
vates only a small fraction of 1% of T cells; in
some cases no activation ensues.
Although the difference between direct and
indirect recognition has been the subject of much
comment, and may be important for the biology
of allografts in some cases, this difference does
not fully explain why allograft rejection is
universal, rapid and severe. Grafts consisting of
allogeneic cells and tissues are fed by blood
vessels of the recipient and the immunological
reaction seems to be directed mainly against
these blood vessels (8, 9); recognition of these
blood vessels must involve the indirect pathway,
that is peptide of the donor presented by MHC
of the recipient. Yet, these grafts are rejected
universally, rapidly and severely. Nor does elim-
inating allogeneic MHC from the surface of all
donor cells prevent or even slow the course of
allograft rejection (10).
If peptide of allogeneic MHC presented indi-
rectly can eventuate powerful rejection reactions,
then the immune system might recognize peptide
of allogeneic MHC differently than peptide of
other proteins. Before association of peptide with
MHC had been proven, Jerne (11) speculated
that the immune system is predisposed to
respond aggressively to allogeneic MHC. Height-
ened immunogenicity of MHC derived peptides
must reflect, at least in part, that peptides from
MHC efficiently loaded on MHC complexes (12).
We found that T cells may be selected by peptides
such as immunoglobulin, encoded by the immu-
noglobulin supragene family (13). MHC with
MHC-derived peptide also interacts distinctly
with TCR. Besides efficient loading, peptides
from MHC might be recognized in some special
way. This idea may explain the distinct structure
of TCR bound to MHC–MHC peptide com-
plexes.
As still another explanation for the universal,
rapid and severe response to allotransplantation,
one might postulate that the allogeneic response
is actually a manifestation of immunological
memory. Generally, a protective response occurs
weeks and sometimes months after the first
exposure to antigen if it occurs at all and full
protection is only exhibited when upon re-expo-
sure to antigen. On the other hand, responses on
first exposure to cells bearing allogeneic MHC
can be detected within a few days. The speed and
intensity of the allogeneic response thus
resembles the speed and intensity of the response
on re-exposure to antigen. Consistent with this
possibility, many of the T cells that respond to
allogeneic cells in human adults are memory T
cells (14). This explanation would place alloim-
mune responses within the framework of con-
ventional immune responses. Some T cell clones
for peptides of cytomegalovirus and perhaps
intestinal flora also respond to allogeneic MHC
(15, 16). Consistent with this concept, but also
subject to other explanations, allogeneic grafts in
the newborn sometimes generate immunity and
sometimes do not (17). Also consistent with the
concept, newborn mice do not reject tumor grafts
Cardiac transplantation in infancy
815
acutely but can still be primed to generate second
set responses (18). One might reason then that
only the newborn and young infants, lacking
immunological memory, might offer clues to
whether the alloimmune response truly differs
from conventional responses.
On the other hand, the lessons taught by
transplantation of the newborn are confounded
by the possibility that transplants might engender
tolerance. Billingham et al. (19) found that
young rabbits reject skin as vigorously as mature
rabbits, but Billingham and Brent (20) found that
newborn mice exhibit a period of non-respon-
siveness. As newborn mice are relatively immu-
no-deficient, this experience would seem to
indicate that the vigorous immune response to
allotransplantation does not require immunolog-
ical memory (we caution however that even a
very small number of memory cells might cause
rejection, given high frequency of alloreactive
cells).
We have begun to explore the response of
infants to allogeneic antigens. Subjects with the
hypoplastic left heart syndrome and other com-
plex cardiac anomalies can be treated surgically
by the Norwood procedure, in conjunction with
which a cuff of allogeneic tissue is inserted and
blood is transfused. Our preliminary analysis
reveals that all of these subjects are sensitized
either to MHC classes I or II antigens (21). While
further analysis is needed, the high rate of
response is consistent with the concept that
allogeneic responses differ from conventional
immune responses.
Tolerance vs. immunity to transplantation in the young
Although exposure of young infants to allogeneic
tissue can induce immunity, transplantation early
in life might instead be able to lead to acquired
immunological tolerance. In the classical exper-
iment, Billingham et al. (17) found that admin-
istration of living haematopoietic cells to mice
early in life changes the recipient in such a way
that subsequent grafts of allogeneic tissue are
retained.
We explored the possibility that introduction
of allogeneic antigen early in life might induce
tolerance rather than immunity by studying
infants with severe defects in cardiac function
who underwent ABO-incompatible cardiac trans-
plantation (22). We found that infants can safely
receive ABO-incompatible cardiac transplanta-
tion because they do not have antibodies against
histo-blood groups A and B substances, as would
normal adults (23). Even more striking however
was our observation that none of the 16 subjects
investigated developed detectable antibodies
against the blood group of the donor but all (of
14 of blood group O) developed antibodies
against the blood group not present in the graft.
Lack of antibody specific for donor blood groups
was not evidently because of binding of anti-
bodies in the graft as graft biopsies showed no
evidence of bound antibody or complement.
Rather, the absence of antibody specific for
donor blood groups reflected acquired immuno-
logical tolerance as B cells of the recipient
cultured in the absence of donor cells or antigen
produced no anti-donor blood group antibody
and because ELISPOT analysis showed a paucity
or absence of B cells capable of recognizing donor
blood group. Normal infants of the same age did
produce such antibodies against the histo-blood
group antigens they lacked because this was a
reflection of specific B-cell tolerance was further
supported by the absence of detectable donor-
antigen-specific B cells by FACS analysis.
Our results show that delivery of blood group
antigens early in life can induce specific immuno-
logical tolerance. Importantly, this form of toler-
ance does not require the administration of
lymphohaemopoietic cells of the donor but appar-
ently can be induced by parenchymal cells con-
taining donor antigen. This clinical experience
mimics animal models of neonatal tolerance.
Tolerance in this setting occurs by elimination of
donor-reactive B lymphocytes and depends upon
continuing expression of antigen. These findings
suggest that intentional exposure to non-self A/B
antigens may prolong the window of opportunity
for ABO-incompatible transplantation, and have
profound implications for clinical research on
tolerance induction to T-independent antigens
relevant to xenotransplantation.
Accommodation after transplantation
We discovered accommodation more than
20 years ago as an unexpected observation
following transplantation of kidneys across
blood group barriers in children (24, 25). Kid-
neys expressing blood groups A or B antigen
were transplanted into recipients lacking those
antigens and having as a result antibodies
directed against those antigens. The anti-blood
group antibodies were depleted and the spleen
removed from the recipients. The kidney trans-
plants functioned well in many cases. Particularly
striking was that antibodies specific for the blood
group antigens returned to the circulation of
some recipients yet the graft appeared not to be
compromised in function or in structure. Biopsies
of the transplants revealed that the blood group
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antigen of the donor was expressed after trans-
plantation as it was before.
We reasoned that the failure of anti-blood
group antibodies to injure the transplanted organ
after the antibodies returned to the circulation
reflected an acquired resistance of the organ to
injury by the antibodies or change in the patho-
genicity of the antibodies. We later excluded the
possibilities that alloreactive antibodies lost
pathogenicity by isotype switching (26), although
such a change might occur in other circumstances
(27, 28). We referred to this condition of acquired
resistance to injury (which could reflect a change
in the pathway by which injury occurs as true
resistance) as ‘‘accommodation’’ (29).
Although the definition for accommodation
we originally put forward (the condition in which
a graft continues to functions in a recipient with
antibodies directed against the graft) would seem
clear, this definition is difficult to apply. Because
normal organs can absorb large amounts of
antibody, we have observed accommodation in
experimental models in which an organ absorbs
all donor-reactive antibodies. Without donor-
reactive antibody, one might find distinguishing
accommodation from tolerance challenging. Also
unclear is whether donor-reactive antibody
induces accommodation or whether other factors
such as cytokines or T cells might do so.
ABO-incompatible transplantation in newborn
and young infants offers what may be the best
opportunity to address those questions. If the
recipient has no antibodies against the donor and
tolerance arises spontaneously as described below,
one might determine whether donor-reactive anti-
bodies are necessary for the development of
accommodation (in those subjects who later
develop antibodies). Our studies to date reveal
no evidence of accommodation in subjects lacking
donor-reactive antibodies. We are also keen to
learn whether tolerance precludes accommoda-
tion and vice versa. If tolerance precludes accom-
modation, as our preliminary studies suggest, then
donor-reactive antibodies may be essential for
accommodation. Conversely, if those which
accommodation cannot have tolerance (as they
make antibodies against the graft), then absence of
accommodation might be taken as evidence of
tolerance [providing accommodation is a common
outcome of organ transplantation as we have
suggested (30, 31)].
Impact of transplantation on the development
of immunity in the young
Immunity, in a classic sense, refers to heightened
resistance to infection in those previously exposed
to an infectious agent, toxins or vaccines. Immu-
nity is conferred by either ‘‘memory T cells’’ or by
antibodies. Defining immunity in this way, one
puts aside for the moment ‘‘natural’’ or ‘‘innate’’
resistance conferred by complement, phagocytes
and other components of the innate immune
system, the other components of what is now
considered to be innate immunity. The developing
of immunity to infectious agents or their products
depends on several components and intercon-
nected events. First, the infectious agent must
provide a source of antigen that can be recognized
by T cells, i.e., antigenic peptide presented in
association withMHC classes I or II molecules on
antigen-presenting cells and delivery of effective
co-stimulatory signals by those cells. Secondly, the
rare T cells capable of recognizing those peptides
must be brought into contact with the antigen-
presenting cells, as occurs typically in regional
lymph nodes and spleen where the T cells are
activated and expansion of protective clones
occur. Thirdly, antigens on the surface of infec-
tious agents and toxins activate B cells committed
to the production of protective antibodies in
conjunction with delivery of signals by helper T
cells that recognize antigenic peptide. Finally,
following the second or subsequent encounter
with the microorganism or its products, the
expanded clones of ‘‘memory’’ T cells and B cells
act quickly to control viral replication or eradicate
bacteria and viruses that enter the body. All of
these events, and especially the second, third and
the final listed should be compromised severely in
those who have undergone cardiac transplanta-
tion in infancy.
Removal of the thymus to facilitate exposure
of the heart prevents the recipient of a cardiac
transplant from generating new T cells. Treat-
ment of the recipient with anti-CD3 or with
thymoglobulin depletes many mature T cells. T
lymphopenia induced by depletion of T cells
causes the remaining T cells to undergo homeo-
static proliferation. In the absence of a thymus,
only homeostatic proliferation can restore T-cell
compartment to the original numbers. Because
new T cells cannot be made, and many mature T
cells have been depleted, the T-cell compartment
of the infant transplant recipient should be
markedly less diverse than the T-cell compart-
ment of a normal individual. To the extent that T
cell diversity determines immune fitness, the
recipient of a cardiac transplant in infancy
should have defective responses. The defect in
function should be worsened profoundly by the
immunosuppressive therapy that so effectively
controls alloimmunity.
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Impact of cardiac transplantation in infancy
on the structure of the T-cell compartment
We tested the assumptions mentioned above
(32). Following removal of the thymus, cardiac
transplantation and depletion of T cells, the
number of T cells in the blood was restored over
a period of months. Restoration of the T-cell
compartment reflected homeostatic proliferation
at least in part because more T cells expressed
markers of memory such as CD45RO. As
expected, removal of the thymus in whole or
part abolished or profoundly reduced the pro-
duction of new T cells as demonstrated by a
profound decrease, and in some cases, absence of
TREC in the blood. TREC are small pieces of
DNA excised from the TCR locus during
formation of the receptor. TREC do not repli-
cate in mitosis and hence the level of TREC in
the blood is a direct function of the output of T
cells by the thymus and an inverse function of
homeostatic proliferation.
If output of the thymus is decreased, as the
profound decrease in TREC suggests, and if
some fraction of mature T cells had been
depleted, the diversity of the T-cell repertoire
should be highly contracted. To test that idea, we
used a novel assay of TCR diversity (33). This
analysis demonstrated that diversity of TCR in
the blood of those who underwent cardiac
transplantation in infancy was contracted by
orders of magnitude (normal people have
roughly one billion different T cells; these
subjects had as few as 1000 different T cells).
One might expect that those who undergo
cardiac transplantation in infancy would have
markedly defective immunological fitness.
Impact of cardiac transplantation in infancy
on immunological competence
While much is known about how the immune
system functions, this knowledge is not reflected
in reliable and quantitative assays of immune
fitness, particularly of the T-cell compartment.
T-cell function and cell-mediated immunity are
typically assayed by determining the number of
T cells in the blood, the ability to mount delayed-
type hypersensitivity responses to Candida or
other common environmental stimuli and
response of T cells to mitogens (34). None of
these assays is likely to detect immunodeficiency
caused by contraction of the T-cell repertoire –
the number of T cells is restored by homeostatic
proliferation, delayed-type hypersensitivity tests
for memory, and the capacity to mount a
primary response and mitogen responses should
be normal.
However, one might explore immune physiol-
ogy more discerningly in those undergoing
transplantation early in life. One could measure
the T-cell-dependant antibody responses to com-
mon vaccines or the levels of viruses that
commonly infect the young. Both approaches
were taken and defects in immunity were
observed. Importantly, those cardiac transplant
recipients with no evidence of thymic function
and contracted T-cell repertoires had 10-fold
higher levels of HHV-7 than those with detect-
able thymic function (32). Thus, from the study
of those who had undergone cardiac transplan-
tation in infancy, we could report for the first
time impact of T-cell diversity on immune
physiology.
Concluding remarks
This communication provides what might be
considered an interim report. We continue to
investigate the structure and function of the
immune system in those undergoing cardiac
transplantation and we expect new insights will
emerge. Yet, we think certain conclusions can be
drawn at this point. First, we consider the
subjects of our investigation and other who
undergo transplantation early in life extraordi-
nary models of immune physiology. These mod-
els allow testing of functions, such as primary
immune responses, that cannot be tested in
adults. Secondly, while we can associate pro-
found contraction of T-cell diversity and treat-
ment with immunosuppressive agents with
abnormalities in cell-mediated immunity, we are
struck that T-cell repertoire contraction and
immunosuppression are not evidently associated
with opportunistic infection characteristic
of inherited or acquired immunodeficiency.
Kulikowska et al. (35) did find that those with
cardiac transplantation in infancy had higher
rates of pyogenic infection, as one might expect
if T-cell-dependant antibody responses are
impaired. However, neither the subjects reported
by Kulikowska et al. (35), nor the subjects we
investigated, had disseminated viral infections or
infections with unusual organisms or unusual
cancers. Either the immune system has the
capacity to compensate for loss of diversity and
impairment in signalling well beyond what is
currently envisioned or the requirements for
immune fitness are far from being well under-
stood. We suspect both.
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